eMIMSplus is a digital medicine reference platform for Australian healthcare professionals, providing access to PBS data and drug interaction tools on iOS and Android.
Product velocity
Maintenance
Daily rank 🇺🇸
—
Medical
Sentiment
—
—
Nemesis
Fragmented field
The App DNA
What makes this app unique?
Clinicians require instant, accurate access to medicine information and PBS pricing during patient consultations, a need eMIMSplus serves by centralizing Australian-specific pharmaceutical data.
For Healthcare professionals including doctors, nurses, pharmacists, and medical students operating within the Australian medical system.
What does it look like?
Key features
Provides Pharmaceutical Benefits Scheme restrictions and pricing for prescribing guidance.
Identifies potentially harmful combinations of medications for clinical safety.
Enables lookup by medicine name, company, or therapeutic action.
How much does it cost?
The model is a B2B subscription service targeting healthcare professionals, requiring external sign-up to unlock the platform.
Velocity
Maintenance developmentnew contentperformanceShow more...
With only one release in the observed window and a last update occurring 139 days ago, the app operates on a maintenance cadence. Development is currently focused on regulatory compliance, specifically updating the National Immunisation Program Schedule, alongside targeted fixes for pregnancy and dental modules. There is no evidence of active feature development or live operations. The current trend indicates a stable but infrequent update cycle focused solely on content maintenance and performance.
Who built it?
MIMS PTE
12 apps tracked · Medical
MIMS Hong Kong
MIMS Philippines
MIMS Vietnam
MIMS Thailand
MIMS Singapore
iMIMS NZ (New)
MIMS Education
eMIMSplus Asia
eMIMSelite
MIMS Indonesia
MIMS MalaysiaUser Sentiment
What do users think recently?
The recent review mood reads frustrated. Users appreciate informative content and clear design make the medical reference tool useful for daily professional tasks.
How are ratings & reviews evolving?
What users say, by theme
- Informative content and clear design make the medical reference tool useful for daily professional tasks
- Login failures prevent users from accessing the app and utilizing their professional work credentials
8 of 8 recent reviews analyzed · limited sample · Frustrated overall
Read the full review analysisUnlock 2 more frustration themes, each backed by review evidence.
Access the full report for freeCompetition
Competitive landscape for eMIMSplus
How's the Medical market?
eMIMSplus holds a specialized position in the Australian medical reference category, with visibility in the Malaysian and Pakistani medical charts. The reliance on a subscription-gated model necessitates high reliability, yet the current login failures create a significant friction point for professional users [1, 2].
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for eMIMSplus
Where is it heading?
The Australian medical reference market is shifting toward high-availability digital tools, and eMIMSplus is currently exposed due to its technical instability. Stabilizing the login flow is essential to maintain its position as a trusted clinical resource, as professional users will quickly migrate to alternatives if access remains unreliable.
- Persistent login failures in the latest version prevent professional access, which directly erodes trust in the platform's reliability for clinical use.
- The current maintenance-only release cadence suggests a lack of active feature expansion, leaving the platform vulnerable to more agile competitors.
The SWOT
- PBS data integration provides a defensible barrier for Australian prescribing guidance
- Implementing dark mode would address a top-requested usability gap for clinical environments
Next best moves
Rebuild authentication flow because login failures are the primary churn driver → restore access to core database
+ 1 more prioritized moveThe counter-intuitive read
The subscription-gated model is an asset, not a liability…
Read the full takeSince the last report: Technical instability has downgraded the platform's market outlook from mixed to declining. The primary shift is the increased urgency of authentication failures, which now threaten the platform's competitive standing in the Australian medical reference market.
Bottom line
Restoring authentication reliability is the immediate priority to prevent professional user churn. Once access is stabilized, addressing the dark mode request will improve the daily experience for clinicians, who currently face visual discomfort during extended use.
Unlock 2 critical frictions, 1 market threat, 1 more prioritized move and the analyst’s take.
Access the full report for freeSources
Report last updated